
Cellular Origins completed an oversubscribed $40M in Series A funding. The round was led by Johnson & Johnson through its corporate venture capital organization Johnson & Johnson Innovation – JJDC Inc. The syndicate included Highland Europe, BGF, NYBC Ventures, and TTP Group.
Cellular Origins is a pioneering developer of an automated robotic manufacturing platform for the industrialisation and digitisation of advanced therapy production. The Company’s differentiated Constellation™ platform – with its combination of mobile robotics, automated sterile welding, workflow software, and integration with leading bioprocess instrumentation – provides a reliable route to scaling complex biomanufacturing processes from 100s of doses to 100,000s, achieving true industrial scale manufacturing.
The funds will be used to accelerate commercial scale-up, on-boarding new clients, new unit operation partners and help Cellular Origins further secure its place at the forefront of scalable cell therapy manufacture.
EC M&A acted as advisor to Cellular Origins on this transaction.